IGC Pharma, Inc. (IGC) Form 10-Q — May 15, 2026
IGC Pharma reported a net loss of $2.4 million for Q1 2026, driven by $1.3 million in R&D and $1.2 million in SG&A expenses, while generating only $317,000 in revenue from non-core life sciences activities. Liquidity tightened significantly, with cash falling 77% to $207,000 and a working capital deficit widening to $1.7 million. The company is increasingly reliant on high-cost convertible debt, having issued notes to Vanquish Funding Group and FirstFire Global Opportunities Fund with aggressive conversion terms. Despite the financial strain, IGC Pharma is advancing its lead Alzheimer’s candidate IGC-AD1 in the Phase 2 CALMA trial, reaching approximately 80% patient enrollment.
Key figures
- Revenue
- 317000
- Total Debt
- 917000
- Revenue Yoy
- -4
- Cash Position
- 207000
- Shares Outstanding
- 98796089
- R And DExpense
- 1272000
- Sg And AExpense
- 1241000
- Digital Asset Investment
- 28000
- Stock Based Compensation
- 1009000
- Convertible Debt Principal
- 353000
Price after filing
Close on the filing date to close N calendar days later (from $0.30). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.